SABCS 2017

CDK4/CDK6 Inhibitors Effective in Older Women, but Have More Side Effects

Phoebe Starr

February 2018, Vol 8, No 2 - Breast Cancer, SABCS 2017

Older patients with hormone receptor–positive, HER2-­negative, metastatic breast cancer derive similar benefit as younger patients who received cyclin-dependent kinase (CDK)4/CDK6 inhibitors as part of their initial endocrine therapy, according to a pooled analysis of clinical trials presented at the 2017 San Antonio Breast Cancer Symposium. [ Read More ]

CDK4/6 Inhibitors vs Chemotherapy for Patients with Metastatic Breast Cancer

Hope S. Rugo, MD

- Breast Cancer, SABCS 2017

Despite international guidelines and data that show CDK4/6 inhibitors plus aromatase inhibitors can improve overall response rates, overall survival, and progression-free survival in patients with metastatic breast cancer, there is a lasting belief among patients that chemotherapy is the preferable course of treatment. Dr. Hope Rugo attempts to dispel this misconception, citing that endocrine therapy and CDK4/6 inhibitors are well tolerated and don’t have the intensive side effects associated with chemotherapy. [ Read More ]